![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Prevalence and Impact of Baseline NS5A Resistance-Associated
Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR)
Against GT1a Infection - 16 Weeks vs 12 weeks
|
|
|
Reported by Jules Levin
AASLD 2016 Nov 13-17 San Francisco
Jacobson IM1; Asante-Appiah E2; Wong P2; Black T2; Howe A2; Wahl J2; Robertson MN2; Nguyen B-Y2;
Shaughnessy M2; Hwang P2; Barr E2; Hazuda D2
1Mount Sinai Beth Israel, New York, NY, USA; 2Merck & Co., Inc., Kenilworth, NJ, USA
![AASLD1.gif](../images/112015/112015-5/AASLD1.gif)
![AASLD2.gif](../images/112015/112015-5/AASLD2.gif)
![AASLD3.gif](../images/112015/112015-5/AASLD3.gif)
![AASLD4.gif](../images/112015/112015-5/AASLD4.gif)
![AASLD5.gif](../images/112015/112015-5/AASLD5.gif)
![AASLD6.gif](../images/112015/112015-5/AASLD6.gif)
![AASLD7.gif](../images/112015/112015-5/AASLD7.gif)
![AASLD8.gif](../images/112015/112015-5/AASLD8.gif)
![AASLD9.gif](../images/112015/112015-5/AASLD9.gif)
![AASLD10.gif](../images/112015/112015-5/AASLD10.gif)
![AASLD11.gif](../images/112015/112015-5/AASLD11.gif)
![AASLD12.gif](../images/112015/112015-5/AASLD12.gif)
![AASLD13.gif](../images/112015/112015-5/AASLD13.gif)
![AASLD14.gif](../images/112015/112015-5/AASLD14.gif)
![AASLD15.gif](../images/112015/112015-5/AASLD15.gif)
![AASLD16.gif](../images/112015/112015-5/AASLD16.gif)
![AASLD17.gif](../images/112015/112015-5/AASLD17.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|